Drug intelligence / Profile preview

CPO-166

Development stage: Unknown
Lead developer: Conjupro Biotherapeutics
Modality: Small Molecules
Administration: Oral

Overview

CPO-166 is an orally bioavailable small molecule inhibitor of cyclin-dependent kinases 2, 4, and 6 (CDK2/4/6) currently under development by CONJ Biotherapeutics. By simultaneously targeting CDK2 along with CDK4 and CDK6, CPO-166 is designed to overcome the resistance mechanisms that frequently emerge during treatment with selective CDK4/6 inhibitors in patients with metastatic breast cancer. The inhibition of these kinases prevents the phosphorylation of the retinoblastoma (Rb) protein, leading to cell-cycle arrest in the G1 phase and the suppression of tumor cell proliferation. The drug is currently being evaluated in Phase 2 clinical trials for the treatment of metastatic breast cancer.

Targets

CDK2 (Cyclin-dependent kinase 2)CDK4 (Cyclin-dependent kinase 4)CDK6 (Cyclin-dependent kinase 6)

Beyond the preview

Go deeper on CPO-166.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CPO-166.

Explore the full profile